جست‌وجوی استاد و پژوهشگر

• Genomics
• Computational Biology
• Cell Biology
• +۵ مورد دیگر

Gioele La Manno is an Assistant Professor (tenure track) at the École Polytechnique Fédérale de Lausanne (EPFL), affiliated with the School of Life Sciences (SV) and the Department of Life Sciences Engineering. He leads the Unité du Prof. La Manno (UPLAMANNO) and holds roles in teaching and doctoral education within the SSV-ENS and Programme doctoral Biologie computationnelle et quantitative . His research focuses on single-cell genomics, cellular heterogeneity, and systems biology approaches to study developmental and neural systems. La Manno’s educational background includes a strong foundation in computational and quantitative biology, reflected in his teaching of courses like Biological data science I: statistical learning and Scientific literature analysis in neuroscience . His lab explores interdisciplinary methods combining genomics, epigenomics, and machine learning to dissect cell fate decisions and tissue organization. He actively contributes to doctoral programs, supervising over a dozen PhD students and advising theses on topics ranging from nervous system development to drug sensitivity profiling. His work bridges basic research with translational applications, such as clinically compliant cell cryopreservation for regenerative medicine. La Manno collaborates across EPFL’s Life Sciences Engineering ecosystem, leveraging state-of-the-art technologies like mass spectrometry imaging and single-cell RNA velocity modeling. His lab’s recent studies address lipidome dynamics, glial diversity in the CNS, and the molecular regulation of midbrain dopaminergic neurons.

• Innate Immunity
• Inflammation
• IBD (Inflammatory Bowel Disease)
• +۶ مورد دیگر

Averil Ma, MD is a Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine. He serves as Director of the UCSF IBD Center and Chief of the Division of Gastroenterology. His research focuses on molecular and cellular mechanisms underlying inflammation and cancer, particularly studying ubiquitin-regulating proteins like A20. He holds notable roles such as Chair of the NIH CMI-A Study Section (2010-2012) and Founding Chair of the KRF Scientific Advisory Board (2009). Education: A.B. in Biochemistry from Harvard College (1980), M.D. from Columbia University (1984), Internal Medicine residency at Massachusetts General Hospital (1987), and Gastroenterology fellowship at Columbia (1989). Research interests include host-commensal interactions in the gut, innate immunity, and ubiquitin-dependent immune regulation. His lab investigates A20’s role in preventing inflammation and cancer via NF-κB signaling, inflammasome control, and tissue integrity. Techniques used include CRISPR, mass spectrometry, and mouse models. Key awards include election to the American Society for Clinical Investigation (2001) and AGA/GRG Young Investigator Award (2001). Publications focus on A20’s functions in inflammation, cancer, and autoimmune diseases, with contributions to understanding ubiquitin pathways and therapeutic targets for IBD, psoriasis, and SLE.

Zheng Zhouمشاهده پروفایل

استاد

• Cell Biology
• Molecular Genetics
• Developmental Biology
• +۳ مورد دیگر

Zheng Zhou is a Professor at the Verna and Marrs McLean Department of Biochemistry and Molecular Biology at Baylor College of Medicine. He is also a member of the Dan L Duncan Comprehensive Cancer Center. His research focuses on the molecular mechanisms of apoptotic and necrotic cell clearance in Caenorhabditis elegans , particularly the recognition, engulfment, and degradation of dying cells. Zhou holds a BS from Fudan University (Shanghai, China) and a PhD in Biochemistry from Baylor College of Medicine. He completed postdoctoral training at MIT and Baylor College of Medicine. His honors include the Norton Rose Fulbright Faculty Excellence Award (2018) and multiple fellowships, including from the Robert A. Welch Foundation and the Rita Allen Foundation. His research interests include understanding how dying cells expose 'eat-me' signals like phosphatidylserine and how phagocytic receptors (e.g., CED-1) mediate clearance. His lab uses genetic screens, live imaging, and molecular tools to study these processes in C. elegans . Recent work highlights roles of calcium signaling in necrotic cell recognition and autophagy-phagocytosis crosstalk in apoptotic cell degradation. Zhou has mentored numerous students and postdocs, including Omar Peña-Ramos (now a postdoc) and Jonathan Pickett. His lab is funded by grants such as an R35 MRA award and an RO1 supplement supporting research on lipid transfer proteins' roles in cell-cell interactions. Labs/Teams: The Zhou Lab at Baylor College of Medicine focuses on programmed cell death and clearance mechanisms. Collaborations include work on dynamin function and signaling pathways in phagocytosis.

John D. Imigمشاهده پروفایل

استاد

• Cardiovascular Research
• Renal Physiology
• Metabolic Disorders
• +۳ مورد دیگر

John D. Imig, Ph.D., is a Professor and Chair of the Department of Pharmaceutical Sciences at the University of Arkansas for Medical Sciences (UAMS). He holds a B.A. in Biology from Blackburn College and a Ph.D. in Physiology & Biophysics from the University of Louisville. His research focuses on understanding how fatty acids influence cardiovascular, kidney, and metabolic functions. The Imig laboratory employs advanced techniques such as animal phenotyping, 3-D/organoid cell culturing, drug design, and omics approaches to develop therapies for cardiovascular, renal, and metabolic diseases. Dr. Imig is a Fellow of the American Heart Association and American Physiological Society, and holds memberships in prestigious organizations including the American Association for the Advancement of Science and the American Society of Nephrology. He has received notable awards such as the Arkansas Research Alliance Scholar (2022), Lewis K. Dahl Memorial Lecture (2019), and the American Heart Association Established Investigator (2004). His research emphasizes multi-target drug development for metabolic diseases, renal fibrosis mechanisms, and the role of epoxylipids in hypertension. Recent studies include investigations into chemotherapy-induced kidney and heart damage, dual enzyme inhibitors, and protective agents for organ transplantation. Collaborative efforts in drug design and omics-based approaches drive translational outcomes for clinical applications. Dr. Imig leads a lab renowned for integrative research spanning basic molecular mechanisms to preclinical drug testing. His work bridges academia and industry, addressing unmet clinical needs in cardiovascular and renal therapeutics. Ongoing projects explore novel therapies targeting epoxide pathways and nuclear receptors to combat chronic diseases.

Taran Raiمشاهده پروفایل

پژوهشگر

• Computational Pathology
• Deep Learning
• Digital Pathology
• +۳ مورد دیگر

Dr. Taran Rai is a Researcher at the University of Surrey, affiliated with the Centre for Vision, Speech and Signal Processing (CVSSP) and the School of Veterinary Medicine. His work focuses on computational pathology, deep learning for medical imaging, and applying AI to veterinary medicine. Rai holds a PhD and has contributed to advancements in necrosis and mitosis detection in canine tumors, leveraging CNNs and digital pathology. His research interests include AI-driven diagnostic tools, social media listening for health insights, and optimizing neural networks for medical applications. He has published extensively on topics like synthetic histopathology data evaluation, diffusion models, and adaptive thresholding methods in pathology. Rai's recent work explores the integration of large language models with medical imaging (e.g., the IPATH dataset) and addresses challenges in veterinary healthcare through social media data. His studies often bridge computational methods with real-world clinical needs, aiming to improve diagnostic accuracy and patient care.

Remy Robertمشاهده پروفایل

دانشیار

• Therapeutic Antibody Development
• Antibody Engineering
• Inflammation
• +۳ مورد دیگر

Remy Robert is an Associate Professor in Physiology at Monash University, affiliated with the Monash Biomedicine Discovery Institute. His primary role is in the Department of Molecular Biology and Biochemistry, focusing on therapeutic antibody development and antibody engineering. He holds a PhD from the University of Bordeaux and completed a postdoctoral fellowship at CSIRO, followed by a research fellowship at Monash University under Professor Charles Mackay. Dr. Robert’s research spans translational medicine, aiming to convert academic discoveries into antibody therapies. His expertise includes protein engineering, autoimmune disease mechanisms, and inflammation modulation. Key projects include the development of bispecific antibodies for cancer immunotherapy, chemokine-targeted therapeutics, and preclinical studies on CCR6-mediated autoimmune diseases. His research outputs emphasize antibody engineering techniques, mouse models of atopic dermatitis, and the role of receptors like GPR109A and CXCR1 in immune regulation. Collaborations involve institutions like CSIRO and global networks in immunology. He leads grants on cancer immunotherapy and has contributed to patents related to antibody technologies. Dr. Robert’s work aligns with UN Sustainable Development Goals focused on good health and well-being. His lab actively pursues innovations in therapeutic antibodies, with a focus on translational applications in oncology and autoimmune diseases.

Tracey Glosterمشاهده پروفایل

پژوهشگر

• Structural Biology
• Enzymology
• CRISPR Mechanisms
• +۳ مورد دیگر

Dr. Tracey Gloster is a researcher in the School of Biology at the University of St Andrews, focusing on the structure and function of carbohydrate processing enzymes and CRISPR-Cas systems. Her work contributes to understanding biological roles of carbohydrates in cellular processes and their malfunction in diseases like cancer and neurodegenerative disorders. She leads projects such as 'Expanding the structural biology toolkit' funded by The Royal Society and has been a PI on Wellcome Trust grants. Research Interests: Carbohydrate processing enzymes (e.g., heparan sulfate degradation) CRISPR-Cas systems and anti-CRISPR proteins Cyclic nucleotide signaling and protein activation mechanisms Structural biology and enzymology Recent Publications Trends: Her articles emphasize CRISPR defense mechanisms, cyclic nucleotide regulation of nucleases, and bioinformatic tools for CAZyme analysis. Key topics include anti-CRISPR proteins, enzyme inhibition strategies, and structural insights into CRISPR effectors. Awards: 2012 Biochemical Society Early Career Research Award 2016 Election to Young Academy of Scotland 2013 L'Oreal-UNESCO For Women In Science Fellowship Grants & Activities: She has secured funding for structural biology projects and collaborates on advanced mass spectrometry tools. Active in organizing workshops (e.g., Scottish Structural Biology) and hosting academic visitors. Served as an external PhD examiner at the University of York. Labs/Teams: Engaged in interdisciplinary research within the Institute of Engineering Biomedical Sciences Research Complex, focusing on structural biology and enzymology applications.

• Membrane Protein Biology
• Protein Synthesis
• Structural Biology
• +۶ مورد دیگر

William M. (Bil) Clemons, Jr. is the Arthur and Marian Hanisch Memorial Professor of Biochemistry at the California Institute of Technology (Caltech), affiliated with the Division of Chemistry and Chemical Engineering. He has held this position since 2007, following roles as Assistant Professor of Chemistry at Caltech (2005-2007) and earlier academic appointments. His research focuses on membrane protein structure, protein synthesis and translocation, and structural biology techniques such as X-ray crystallography. Education: B.S. from Virginia Polytechnic Institute and State University (1995), Ph.D. from the University of Utah (2000). Research Interests: The Clemons Lab investigates molecular mechanisms of protein transport across membranes, post-translational modifications like glycosylation, and challenges in membrane protein overexpression. Current projects include the Sec/Tat membrane translocation pathways, eukaryotic glycosylation processes, and the Get3 chaperone system for tail-anchored proteins. Techniques employed include X-ray crystallography, biochemistry, mass spectrometry, and electron microscopy. Publications reflect a blend of experimental structural biology and discussions on equity in science, including studies on phage antibiotics, DPAGT1 inhibitors, and the experiences of Black scientists in biophysics. His work bridges fundamental biological mechanisms with translational applications in drug design. Teaching and Mentorship: Prof. Clemons instructs courses like Ch/Bi 110 (Biochemistry) and contributes to advanced seminars (BMB/Ch 202, BMB/Bi/Ch 173). His lab emphasizes training diverse early-career scientists in structural biology, believing inclusivity drives scientific innovation.

Sam Butterworthمشاهده پروفایل

استاد

• Medicinal Chemistry
• Cancer Therapy
• Synthetic Chemistry
• +۴ مورد دیگر

Sam Butterworth is a Professor of Medicinal Chemistry at the University of Manchester, holding the Chair in Medicinal Chemistry. Previously, he worked at the University of Birmingham (2013-2016) and AstraZeneca (2005-2013), where his research contributed to the development of osimertinib (Tagrisso), an FDA-approved anti-cancer drug targeting EGFR mutations. He leads the Butterworth Group, focusing on synthetic and biological chemistry to address human health challenges, particularly cancer therapy and drug delivery systems. Education & Experience: Senior Lecturer at Manchester (2016-2024), AstraZeneca R&D (2005-2013), Birmingham academic role (2013-2016) Key Projects: ERK5 inhibitors for breast cancer, nanoparticle drug delivery, and HDX mass spectrometry for protein dynamics Research Interests: Medicinal chemistry, synthetic organic methods, targeted cancer therapies, nanoparticle systems, and enzyme modulators (e.g., NAMPT). His group collaborates closely with clinicians and biomedical researchers to validate compounds in disease models. Publications: Over 25 peer-reviewed articles in journals like Angewandte Chemie and Acta Pharmaceutica Sinica B , focusing on catalytic methods, drug design, and nanotechnology. Awards: 2017 RSC Malcolm Campbell Award, 2018 ACS Heroes of Chemistry Award Grants/Leadership: Co-Investigator on projects totaling £[X] funding, including EPSRC and Wellcome Trust grants Labs & Teams: Active in Manchester’s Institute of Inflammation and Repair and collaborates with the Christie NHS Foundation Trust for translational cancer research.

Hilary Ann Collerمشاهده پروفایل

استاد

• Cellular Quiescence
• Cancer Biology
• Metabolism
• +۴ مورد دیگر

Hilary Ann Coller is a Professor at the University of California, Los Angeles (UCLA), jointly appointed in the Department of Molecular, Cell and Developmental Biology and the Department of Biological Chemistry within the College of Letters and Science. She leads a research laboratory focusing on cellular quiescence, metabolism, and their implications in cancer and disease progression. Her research integrates molecular biology, epigenetics, and systems approaches to study: Transcriptional and epigenetic control of quiescence Metabolic adaptations in tumor microenvironments RNA biology and gene regulation networks Development of biomedical technologies (e.g., biosensors) Recent publications (2022–2025) highlight trends in: Cellular quiescence mechanisms and transcription factor dynamics Cancer epigenetics and metabolic reprogramming Innovative tools for metabolomics and drug monitoring Educational research on remote STEM training programs She directs multiple NIH-funded projects, including R01CA221296 (stromal autophagy in melanoma) and R01GM086465 (microRNA mechanisms). Her lab mentors graduate students and postdocs, and she co-leads UCLA’s Bruins-in-Genomics summer initiative for undergraduate computational biology training.

Zulfiya Orynbayevaمشاهده پروفایل

استادیار

• Mitochondrial Pathophysiology
• Nanomedicine
• Cancer Therapeutics
• +۳ مورد دیگر

Zulfiya Orynbayeva, PhD, is an Assistant Professor in the Department of Surgery at Drexel University College of Medicine. Her research focuses on mitochondria pathophysiology and nanomedicine, particularly investigating energy metabolism in cancer, neurodegeneration, and reproductive system pathologies. Education: MSc and PhD in Biophysics from Tashkent State University (1984-1993). Research Interests : - Mitochondrial dysregulation in tumors and its role in metabolic adaptation - Development of anti-cancer therapies targeting mitochondrial energy pathways - Oocyte competence and mitochondrial energy requirements - Single-cell array nanotechnologies for metabolic analysis Techniques : Oxygraph-2K for mitochondrial screening, optical spectroscopy, amperometric methods, and nanoscale probes. Patent : A method and apparatus for measuring biological activity with single-cell resolution (US10253289, 2015). Contact: zulfiya.orynbayeva@drexelmed.edu | Department of Surgery, Drexel University College of Medicine.

Jose M Silvaمشاهده پروفایل

استاد

• Cancer Biology
• Cancer Genetics
• Tumorigenesis
• +۵ مورد دیگر

Jose M Silva is a Professor in Pathology and Oncological Sciences at Columbia University Medical School. He holds adjunct faculty status and has prior roles including Assistant Professor at Columbia and postdoctoral training at Cold Spring Harbor Laboratory. His research focuses on cancer genomics, functional networks, and translating discoveries into clinical applications. He has pioneered integrative approaches combining genomics and systems biology to identify critical cancer cell regulators, leading to clinical trials. Education: BSc, Complutense University of Madrid PhD, Autonoma University of Madrid PostDoc & Senior Fellow, Cold Spring Harbor Laboratory Research Interests: His lab investigates breast cancer development and therapeutics, including molecular characterization of tumor networks, novel drug targets (e.g., RSF1, BIN3), and clinical translation of discoveries. Current efforts target triple-negative breast cancers and aging-cancer intersections. Grants & Trials: Initiated NCT02066532 clinical trial; ongoing work includes HDAC6/STAT3 inhibition studies and single-cell atlas projects.

Marc Therrienمشاهده پروفایل

استاد

• Signal Transduction
• Cancer Biology
• Cell Signaling
• +۳ مورد دیگر

Marc Therrien is a Full Professor at the Department of Pathology and Cellular Biology, Faculty of Medicine, University of Montreal. He leads the Unité de recherche en signalisation intracellulaire at the IRIC (Institut de recherche en immunologie et en cancérologie). His research focuses on the RAS-MAPK signaling pathway, particularly its role in cell proliferation, differentiation, and cancer development. He has held the Canada Research Chair in Intracellular Signalling since 2004. Education : PhD in Biochemistry from University of Montreal (1993) Postdoctoral training at UC Berkeley with Gerald M. Rubin (1993–1999) Research Interests : His lab uses Drosophila genetics and molecular biology to study signaling proteins in the RAS pathway, including KSR and CNK. Key projects involve identifying therapeutic targets for cancers linked to RAS pathway mutations. Recent work includes elucidating mechanisms of RAF kinase activation and developing inhibitors targeting RAS-MAPK signaling. Grants & Awards : Multiple grants from the Canadian Institutes of Health Research (CIHR), FRQS, and others Canada Research Chair renewals (2004, 2009, 2017) 2011 Quebec Science Top 10 Discovery for work on the EJC complex Advising & Labs : Supervised over 10 PhD and Master’s students Leads the IRIC’s signal transduction research unit Collaborates with teams on drug discovery for cancer Labs & Teams : His lab is part of the IRIC, a center focused on translational cancer research. Current projects include developing inhibitors for RAS-driven cancers and investigating CNK2’s role in metastasis.

• Exercise Oncology
• Cancer Rehabilitation
• Prostate Cancer Treatment
• +۳ مورد دیگر

Professor Daniel Galvão is a leading academic in exercise oncology at Edith Cowan University (ECU), Australia. He serves as Director of the Exercise Medicine Research Institute and holds a Professorship in Exercise and Sports Science within the School of Medical and Health Sciences. His research focuses on optimizing exercise interventions to mitigate treatment-related toxicities and improve outcomes for cancer patients, particularly those with prostate cancer. Galvão has secured over $26 million in grants from bodies like the NHMRC, Movember Foundation, and Cancer Australia, supporting multidisciplinary trials and survivorship programs. Education: PhD (Edith Cowan University, 2006), Master of Applied Science in Clinical Exercise Science (University of Queensland, 2003). His career includes roles as Co-Director of ECU’s Health and Wellness Institute and Fellowships with the American College of Sports Medicine and Exercise and Sports Science Australia. Research emphasizes exercise as medicine in oncology, with over 200 peer-reviewed publications. Key contributions include guidelines for exercise in cancer patients and landmark trials like ERADICATE (prostate cancer radiotherapy adjuncts) and TelEX (weight management for prostate cancer). Notable awards include the 2021 Asian Pacific Prostate Cancer Conference Best Poster, 2014 Edith Cowan Vice-Chancellor’s Award, and 2007 ESSA PhD Medal. He chairs national research committees and reviews for high-impact journals like Journal of Clinical Oncology and European Urology . Current initiatives include nationwide exercise programs for prostate cancer survivors and translational research on myokine mechanisms in cancer suppression. His work bridges clinical practice with evidence-based interventions to enhance patient quality of life and survival outcomes.

Carmen Birchmeierمشاهده پروفایل

استاد

• Developmental Biology
• Cell Biology
• Neuroscience
• +۳ مورد دیگر

Carmen Birchmeier is a Full Professor at the Medical Faculty of Charité - Universitätsmedizin Berlin and a leading researcher at the Max Delbrück Center for Molecular Medicine (MDC). She coordinates the MDC Neuroscience Program and serves on the Executive Board of the NeuroCure Cluster of Excellence. Her research focuses on developmental biology, cell signaling, and the molecular mechanisms underlying nervous system and muscle development. Education: PhD in Molecular Biology from the University of Zürich (1984), followed by postdoctoral training at Cold Spring Harbor Laboratory (1984–1989). She established her independent research group at the Max Delbrück Lab in Cologne (1989–1995) before moving to Berlin. Research Interests: Investigates signal transduction pathways (e.g., Notch, ErbB, and c-Met) in developmental processes, including neural crest cell migration, muscle progenitor cell differentiation, and Schwann cell myelination. Her work bridges molecular genetics, mouse models, and cellular biology to uncover mechanisms of tissue formation and disease. Awards: Recipient of the Leibniz Award (2002) and EMBO Membership (2001). Her contributions to developmental neurobiology have been recognized internationally. Leadership & Grants: Deputy Speaker of SFB 665 (Developmental Disturbances of the Brain), DFG Fachkollegium Member, and advisor to multiple institutes including the Max Planck Institute for Biophysical Chemistry. Her work spans academic and clinical research collaborations. Labs/Teams: Heads the Signal Transduction/Developmental Biology Research Group at MDC, focusing on interdisciplinary approaches to understand developmental disorders and regenerative medicine strategies.